Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Cytokine Release Syndrome Management Market Size Changed, over the years?
The market size for managing cytokine release syndrome has seen considerable growth in the past few years. The market is projected to expand from $22.32 billion in 2024 to $23.83 billion in 2025, representing a compound annual growth rate (CAGR) of 6.8%. Factors such as increased healthcare spending, enhanced awareness, lifestyle changes, higher disposable income, the embrace of personalized medicine methods, and the growing utilization of targeted treatments have contributed to this historic period growth.
How Much Will the Cytokine Release Syndrome Management Market Be Worth in 2029?
The market for managing cytokine release syndrome is anticipated to witness considerable expansion in the upcoming years, and is predicted to rise to $30.69 billion by 2029, demonstrating a CAGR of 6.5%. This progression in the projected timeframe can be linked to the increased demand for diagnostic tools and treatment options, enhanced government support, a growing appeal for efficient therapies, an increasing aging population, and the introduction of initiatives by public and private entities. Key trends during this projection period include the application of minimally invasive devices for breast biopsies, the establishment of strategic alliances and collaborations, the provision of antibiotic infusion services at home, the development of new drug delivery systems, and the incorporation of electronic health records into infection tracking.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24199&type=smp
Which is the Largest Company in the Cytokine Release Syndrome Management Market?
Major companies operating in the cytokine release syndrome management market are Pfizer Inc., Johnson & Johnson Private Limited, F. Hoffmann-La Roche Ltd., AbbVie Inc., Sanofi S.A., Bristol Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Genentech Inc., Incyte Corporation, Swedish Orphan Biovitrum AB, Biocon Limited, MacroGenics Inc., Legend Biotech Corporation, Bluebird Bio Inc., InflaRx N.V., Humanigen Inc.
What Are the Main Market Drivers in the Cytokine Release Syndrome Management Industry?
The cytokine release syndrome management market is expected to continue growing owing to the escalating use of targeted therapies. These treatments and drugs are specifically curated to hinder cancer’s growth and expansion by disrupting molecular objectives involved in tumor creation. The increasing preference for targeted therapies primarily results from their capacity to target cancer cells accurately whilst minimizing harm to healthy cells, enhancing the potency of treatment, and decreasing side effects compared to conventional therapies. Management of cytokine release syndrome plays a pivotal role in refining targeted therapies by regulating intense inflammatory reactions, thereby improving the safety and effectiveness of treatments such as CAR-T cell therapy and immune checkpoint inhibitors. For example, the American Society of Gene and Cell Therapy, a US-based gene and cell therapy entity, reported in January 2024 that there was a 10% increase in Phase III clinical trials of gene therapies in the last quarter of 2023. This was the initial quarterly surge of this kind since the third quarter of 2022. Thus, the growth of the cytokine release syndrome management market is being propelled by the escalated usage of targeted therapies.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24199&type=smp
How Is the Cytokine Release Syndrome Management Market Segments Structured?
The cytokine release syndrome management market covered in this report is segmented –
1) By Treatment Type: Monoclonal Antibodies, Corticosteroids, Intravenous Immunoglobulin (IVIG), Targeted Therapy, Supportive Care, Other Treatment Types
2) By Indication: Chimeric Antigen Receptor (CAR) T-Cell Therapy, Immune Checkpoint Inhibitors, Hematopoietic Stem Cell Transplantation (HSCT), Autoimmune Diseases, Infections, Other Indications
3) By Route Of Administration: Intravenous (IV), Subcutaneous (SC), Oral, Intramuscular (IM), Intrathecal, Other Routes Of Administration
4) By End Users: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics, Research Institutions, Other End Users
Subsegments:
1) By Monoclonal Antibodies: Tocilizumab, Siltuximab, Infliximab, Rituximab, Other Monoclonal Antibodies
2) By Corticosteroids: Dexamethasone, Prednisone, Methylprednisolone, Hydrocortisone, Other Corticosteroids
3) By Intravenous Immunoglobulin (IVIG): Immunoglobulin G (IgG)-Based Intravenous Immunoglobulin, Immunoglobulin A (IgA)-Based Intravenous Immunoglobulin, Immunoglobulin M (IgM)-Based Intravenous Immunoglobulin, Polyvalent Intravenous Immunoglobulin, Other Types of Intravenous Immunoglobulin
4) By Targeted Therapy: Janus Kinase (JAK) Inhibitors, Interleukin-6 (IL-6) Inhibitors, Tumor Necrosis Factor-Alpha (TNF-a) Inhibitors, Bruton’s Tyrosine Kinase (BTK) Inhibitors, Other Targeted Agents
5) By Supportive Care: Antipyretic Medications, Analgesic Medications, Intravenous Fluids And Electrolyte Solutions, Oxygen Therapy, Vasopressor Agents
6) By Other Treatment Types: Plasmapheresis (Therapeutic Plasma Exchange), Antihistamine Medications, Leukapheresis, Experimental Therapies, Nutritional Support
What Strategic Trends Are Transforming the Cytokine Release Syndrome Management Market?
Leading corporations within the cytokine release syndrome management market are concentrating their efforts on running clinical trials in pursuit of novel therapies. These include host-oriented small molecule pharmaceuticals intended to moderate immune responses and mitigate the harshness of cytokine tempests, without undermining the body’s capacity to combat infections or cancer. A host-directed small molecule is a compound with a low molecular weight that targets the host’s immune signaling pathways to curb excessive cytokine creation, subsequently assisting in managing cytokine release syndrome (CRS) by averting overactivation of the immune system. For example, in April 2025, the American biotech company, CytoAgents Inc., publicized the successful conclusion of the initial dose-escalation group in its Phase 1b/2a clinical experiment of CTO1681. This host-directed small molecule prescription was developed to avert and treat CRS in patients undergoing CAR T-cell therapy. The exploratory therapy showed an advantageous safety track record, with no dose-limiting toxicity or interference with CAR T-cell effectiveness. The trial, which employs a rolling six dose-escalation methodology, aims to evaluate the safety, tolerability, initial effectiveness of CTO1681 and to determine the advisable phase 2 dosage.
Access The Full Report Here:
Which Global Regions Offer the Highest Growth in the Cytokine Release Syndrome Management Market?
North America was the largest region in the cytokine release syndrome management market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cytokine release syndrome management market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/customise?id=24199&type=smp
This Report Delivers Insight On:
1. How big is the cytokine release syndrome management market, and how is it changing globally?
2. Who are the major companies in the cytokine release syndrome management market, and how are they performing?
3. What are the key opportunities and risks in the cytokine release syndrome management market right now?
4. Which products or customer segments are growing the most in the cytokine release syndrome management market?
5. What factors are helping or slowing down the growth of the cytokine release syndrome management market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model